Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA accepts Dimension Therapeutics' IND for DTX-301

Dec. 14, 2016

European Commission approves Ferring's Rekovelle

Dec. 14, 2016

Defymed collaborates with Semma Therapeutics to develop innovative treatment for type 1 diabetes

Dec. 13, 2016

Eiger BioPharmaceuticals reports interim results from phase II study of exendin 9-39 in PBH

Dec. 13, 2016

BioMarin Pharmaceutical begins phase III study of vosoritide in achondroplasia

Dec. 13, 2016

Amicus Therapeutics reports data from phase I/II study of ATB-200/AT-2221

Dec. 9, 2016

FDA grants orphan drug designation to VK-0214 for X-linked adrenoleukodystrophy

Dec. 9, 2016

Beijing Institute of Pharmacology and Toxicology patents CB1 receptor antagonists

Dec. 7, 2016

TherapeuticsMD discloses topline results from Replenish trial of TX-001HR

Dec. 7, 2016

Novo Nordisk submits applications in E.U., U.S. for semaglutide

Dec. 7, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...